Roche will present new data from nine approved and investigational medicines at the 2026 ASCO meeting. A major focus is giredestrant, an oral SERD, being tested for ER-positive, HER2-negative breast cancer. Data from the lidERA study will explore giredestrant's efficacy across menopausal stages in early breast cancer. The persevERA study revealed numerical improvements in progression-free survival with giredestrant plus palbociclib. Analyses of evERA will address sustained clinical benefit after progression on CDK4/6 inhibitors. Preliminary results will be shared for ZN-A-1041, a blood-brain barrier-permeable HER2 TKI in HER2-positive breast cancer. The Krascendo 170 study will present data on the KRAS G12C inhibitor divarasib combined with pembrolizumab in lung cancer. Updated findings from the SUNMO trial will support the effectiveness of Lunsumio plus Polivy in DLBCL. Roche's presentation also encompass a variety of innovative treatments for multiple types of cancer. The company is committed to addressing cancers with a high burden on patients and society.